Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bard Surgery, Vascular Offerings Lead Q1 Growth; Margins Help Boost R&D

This article was originally published in The Gray Sheet

Executive Summary

FDA has indicated that Bard's anti-infection endotracheal tube will be regulated as a device/drug combination product, the firm says

You may also be interested in...



Bard Vascular Unit To Do Heavy Lifting As Hernia Sales Growth Slows

Bard is reevaluating its programmable pain pump strategy due to developmental delays caused by imaging technology compatibility issues

Bard Vascular Unit To Do Heavy Lifting As Hernia Sales Growth Slows

Bard is reevaluating its programmable pain pump strategy due to developmental delays caused by imaging technology compatibility issues

Bard clarification

Firm's anti-infection endotracheal tube is coated with a new formulation of silver hydrogel anti-microbial technology internally developed by Bard and specifically formulated to address ventilator-associated pneumonia. The device does not use BactiGuard technology, as previously reported (1"The Gray Sheet" April 21, 2003, p. 21)...

Related Content

UsernamePublicRestriction

Register

MT018217

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel